Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

Abstract Background Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate the role of alpha-fetoprotei...

Full description

Bibliographic Details
Main Authors: Hong-Fei Zhu, Jin-Kai Feng, Yan-Jun Xiang, Kang Wang, Li-Ping Zhou, Zong-Han Liu, Yu-Qiang Cheng, Jie Shi, Wei-Xing Guo, Shu-Qun Cheng
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma (HCC)
Immune checkpoint inhibitor (ICI)
Immunotherapy
Predictive score
Overall survival (OS)
Progression-free survival (PFS)
Online Access:https://doi.org/10.1186/s12885-023-11003-0

Internet

https://doi.org/10.1186/s12885-023-11003-0

Similar Items